EDT Spectral Medical

Spectral Medical to Present at the H.C. Wainwright Virtual BioConnect Conference

Spectral Medical to Present at the H.C. Wainwright Virtual BioConnect Conference

TORONTO, Jan. 11, 2021 (GLOBE NEWSWIRE) -- Spectral Medical Inc. (“Spectral” or the “Company”) (TSX: EDT), a late stage theranostic company advancing therapeutic options for sepsis and septic shock, as well as commercializing a new proprietary platform targeting the renal replacement therapy market through its wholly-owned subsidiary Dialco Medical Inc. (“Dialco”), today announced that it will be presenting at the H.C. Wainwright Virtual BioConnect Conference, being held January 11 – 14, 2021. Dr. Paul Walker, President and CEO, and Chris Seto, COO and CFO of Spectral Medical Inc. will be hosting the presentation.

About Spectral

Spectral is a Phase III company seeking U.S. FDA approval for its unique product for the treatment of patients with septic shock, Toraymyxin™ (“PMX”). PMX is a therapeutic hemoperfusion device that removes endotoxin, which can cause sepsis, from the bloodstream and is guided by the Company’s Endotoxin Activity Assay (EAA™), the only FDA cleared diagnostic for the risk of developing sepsis.

PMX is approved for therapeutic use in Japan and Europe, and has been used safely and effectively on more than 200,000 patients to date. In March 2009, Spectral obtained the exclusive development and commercial rights in the U.S. for PMX, and in November 2010, signed an exclusive distribution agreement for this product in Canada. Approximately 330,000 patients are diagnosed with severe sepsis and septic shock in North America each year.

Spectral, through its wholly owned subsidiary, Dialco Medical Inc., is also commercializing a new proprietary platform, “SAMI”, targeting the renal replacement therapy (“RRT”) market.  Dialco is also seeking regulatory approval for in-home use of “DIMI” which is based on the same RRT platform, but will be intended for home hemodialysis use.  “DIMI” recently received its FDA 510k clearance for use in hospital and clinical settings.

Spectral is listed on the Toronto Stock Exchange under the symbol EDT. For more information, please visit .

Contact:

Dr. Paul Walker 

President and CEO 

Spectral Medical Inc.

416-626-3233 ext. 2100 

Mr. Chris Seto 

COO & CFO 

Spectral Medical Inc.

416-626-3233 ext. 2004 

 
Ali Mahdavi

Capital Markets & Investor

Relations

416-962-3300

   
David Waldman/Natalya Rudman

US Investor Relations

Crescendo Communications, LLC

212-671-1020

  



EN
11/01/2021

Underlying

To request access to management, click here to engage with our
partner Phoenix-IR's CorporateAccessNetwork.com

Reports on Spectral Medical

 PRESS RELEASE

Spectral Medical Sponsors Unite for Sepsis Symposium, Chicago Septembe...

Spectral Medical Sponsors Unite for Sepsis Symposium, Chicago September 8 – 9, 2025 Company to present at session titled “Personalizing Sepsis Treatment” TORONTO, Sept. 08, 2025 (GLOBE NEWSWIRE) -- Spectral Medical Inc. (“Spectral” or the “Company”) (TSX: EDT), a late-stage theranostic company advancing therapeutic options for sepsis and septic shock, today announced its sponsorship of the Unite for Sepsis Symposium, taking place September 8 – 9, 2025, in Chicago, Illinois. The Company also announced that Debra Foster, Clinical Consultant at Spectral Medical, will participate in a feat...

 PRESS RELEASE

Spectral Medical Receives US$3 Million From Vantive

Spectral Medical Receives US$3 Million From Vantive TORONTO, Aug. 25, 2025 (GLOBE NEWSWIRE) -- Spectral Medical Inc. (“Spectral” or the “Company”) (TSX: EDT), a late-stage theranostic company advancing therapeutic options for sepsis and septic shock, today announced that it has received the US$3 million Tranche B advance from Vantive US Healthcare LLC (“Vantive”) pursuant to the previously disclosed senior secured promissory note entered into in May 2025. The Tranche B advance further strengthens Spectral’s balance sheet and will be used to support ongoing regulatory and commercializatio...

 PRESS RELEASE

Spectral Medical and Vantive Announce Topline Results from Spectral’s ...

Spectral Medical and Vantive Announce Topline Results from Spectral’s Tigris Trial Evaluating PMX Hemoadsorption Therapy for Endotoxic Septic Shock Results exceed prespecified primary endpoint of 95% posterior probability of benefit for PMX on 28-day mortality Pooled absolute risk reduction of 8.3%; Relative risk reduction of 18% Key secondary endpoint: 90-day Mortality 17.4% lower with PMX and >99% posterior probability of benefit 38.7% Mortality at 28 days with PMX confirms results of prior trial subset TORONTO, Ontario and DEERFIELD, Ill., Aug. 12, 2025 (GLOBE NEWSWIRE) -- Spectra...

 PRESS RELEASE

Spectral Medical Announces Second Quarter and Provides Corporate Updat...

Spectral Medical Announces Second Quarter and Provides Corporate Update Topline Tigris results expected to be released around mid-August 2025 TORONTO, Aug. 08, 2025 (GLOBE NEWSWIRE) -- Spectral Medical Inc. (“Spectral” or the “Company”) (TSX: EDT), a late-stage theranostic company advancing therapeutic options for sepsis and septic shock, today announced its financial results for the second quarter and provided a corporate update. The second quarter of 2025 marked significant clinical and operational progress for Spectral. Following the completion of patient enrollment in the Tigris tri...

 PRESS RELEASE

Spectral Medical Inc. Announces Filing of Base Shelf Prospectus

Spectral Medical Inc. Announces Filing of Base Shelf Prospectus TORONTO, July 04, 2025 (GLOBE NEWSWIRE) -- Spectral Medical Inc. (“Spectral” or the “Company”) (TSX: EDT), a late-stage theranostic company advancing therapeutic options for sepsis and septic shock, today announced that it has filed a preliminary short form base shelf prospectus with the securities regulatory authorities in each of the provinces of Canada, except Québec (the “Securities Regulators”). The base shelf prospectus, when made final, will allow Spectral to qualify the distribution by way of a prospectus of up to $1...

ResearchPool Subscriptions

Get the most out of your insights

Get in touch